Press Room

ViSync® Technologies, a joint venture between Hovione, a global specialist integrated CDMO and leader in spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnológica), a not-for-profit R&D institution specializing in Biotechnology and Life Sciences, is proud to announce the appointment of Elsa Abranches as its Chief Scientific Officer (CSO). Headquartered in Oeiras, Portugal, ViSync® Technologies was established to address unmet technological needs in the pharmaceutical industry, focusing on developing innovative solutions for the cell and gene therapy space. By leveraging Hovione's expertise in pharmaceutical development, particle engineering, and industrialization, alongside iBET’s pioneering research in biotechnological sciences, ViSync® is uniquely equipped to drive innovation in targeted delivery and stabilization of next-generation therapies.  Dr. Elsa Abranches brings over two decades of experience in cell and gene therapy, with a strong track record of leading diverse teams in dynamic environments. In her new role as ViSync® CSO, she will drive the company’s R&D strategy and scientific vision, positioning ViSync® as a leader in innovation within the dynamic and rapidly advancing field of cell and gene therapy. “We are thrilled to welcome Elsa Abranches as Chief Scientific Officer of ViSync®,” said Dr. Christoph Bruecher, Chairman of the Board of ViSync® and VP Business Transformation at Hovione. “Her expertise and vision in the field of advanced therapeutics will be pivotal in driving ViSync’s mission to create transformative solutions that empower pharmaceutical companies and improve patient treatment outcomes.” Dr. Manuel Carrondo, Director of the Board of ViSync® and Vice President of iBET, added, “Elsa’s appointment underscores our commitment to establishing ViSync® as a leader in cell and gene therapy innovation. Her scientific leadership will be critical as we tackle some of the most pressing challenges in the field of new modalities drug delivery.” Elsa Abranches, new Chief Scientific Officer of ViSync®, said: “Having worked in different countries and industries, I’m thrilled to bring my experience back home to join ViSync®. This new venture represents an incredible opportunity to collaborate with local and international partners to drive innovation in advanced therapeutics and help shape the future of life-changing therapies”.     About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About iBET iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET’s core expertise lies on the development of bioprocesses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing. iBET’s infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies. iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders.     

News
ViSync® Technologies, a joint venture between Hovione and iBET is proud to announce the appointment of Elsa Abranches as its Chief Scientific Officer (CSO).

ViSync® Technologies appoints Elsa Abranches as Chief Scientific Officer

Dec 19, 2024

Lisbon, November 25, 2024, Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in Europe and the USA. The investments at its East Windsor, New Jersey, and Ringaskiddy, Cork, facilities will significantly increase Hovione's global spray drying capacity and enhance the sites‘capabilities.   This latest round of investment reinforces Hovione’s position as the global leader in spray drying for pharma applications, an essential technology for enhancing drug solubility and bioavailability. Spray drying converts liquid solutions into fine powders, enabling improved dissolution and absorption of poorly water-soluble drugs. This process is particularly valuable for inhalable therapies and oral formulations with low bioavailability, helping to deliver more effective treatments and ensuring reliable, high-quality healthcare solutions for patients.  In New Jersey, the investment represents the first step of a multi-year site expansion program, aimed at advancing both spray drying and tableting capabilities. Simultaneously, the Cork facility saw its spray drying capacity increase nearly twofold. Combined, these efforts are creating over 40 new skilled jobs, driving growth and innovation across both locations. Dr Jean-Luc Herbeaux, Chief Executive Officer of Hovione said: “These expansions, incorporating our latest technologies, reflect Hovione’s unwavering commitment to innovation and manufacturing service excellence. Strengthening our facilities and teams in the USA and Ireland allows us to better serve our customers and provide flexible supply options for both small- and large-scale programs. By increasing our capacity and enhancing our technological capabilities, we are even better equipped to help our customers bring new and more complex drugs to market.” The investments at both sites are part of Hovione’s long-term strategy to remain at the forefront of pharmaceutical technology. With a 65-year history of continuous improvement, Hovione is driving progress in drug development and manufacturing, offering solutions that enable more effective treatments and improved patient outcomes.   About Hovione:  Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   In the picture from left to right: Dr. Till Riehm, Site Manager - Cork, Hovione; Dr. Jean-Luc Herbeaux, CEO, Hovione; Michael McGrath, the European Commissioner Designate for Democracy, Justice and the Rule of Law; Michael Lohan, CEO, IDA Ireland; Jorge Pastilha, VP Technical Operations - Europe and Asia, and Dr. Paul Downing, Senior Director, Strategic Business Management.    

Press Release
Hovione has completed significant expansions at its facilities in New Jersey, USA, and Cork, Ireland.

Hovione Expands Global Spray Drying Capacity with Significant Investment in the USA and Ireland

Nov 26, 2024

International pharmaceutical contract development and manufacturing organisation (CDMO) Hovione has today officially commissioned an expansion at its manufacturing facility in Ringaskiddy. The multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. Hovione said this latest investment reinforces the company's position as a global leader in spray drying for pharma applications.   This manufacturing technology, the company explained, is "especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments".  Deputising for the Mayor of the County of Cork, councillor Audrey Buckley said:  “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today.  “It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” Meanwhile Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law, welcomed the expected jobs boost the expansion is to create.  “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector.  “I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. Jean-Luc Herbeaux, Hovione's chief executive said: “This newly opened facility further strengthens Hovione's position as the global CDMO of choice for spray drying development and manufacturing services.  “It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores.  “Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” CEO of IDA Ireland, Michael Lohan, said Hovione "has made a significant contribution both locally and nationally through employment and investment alike". "We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success," he added.    Read the full article on EchoLive.ie    

Press Clipping
EchoLive, 25 November 2024

Pharma company announces expansion of Cork facility to create more than 20 new jobs

Nov 25, 2024

Pharmaceutical contract development and manufacturing company Hovione has officially commissioned an expansion at its manufacturing facility in Ringaskiddy, Cork.  Announcing the development on Monday, the multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions. This manufacturing technology is especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments, the company said. Deputising for the Mayor of the County of Cork, Cllr. Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today.  "It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.”  Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law said: “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector. "I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”. This latest investment builds on the momentum of the recently announced spray drying capacity expansion at the Company's East Windsor, New Jersey, site.  Jean-Luc Herbeaux, Hovione´s Chief Executive said: “This newly opened facility further strengthens Hovione´s position as the global CDMO of choice for spray drying development and manufacturing services.  "It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.” IDA chief executive Michael Lohan said the company has made a significant contribution both locally and nationally, adding: "I am pleased to be here today to mark another step on that journey. We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success.”   Read the full article on IrishExaminer.com  

Press Clipping
Irish Examiner, 25 November 2024

Pharma company Hovione to double capacity at Cork site as part multi-million euro investment

Nov 25, 2024

Lisbon, October 3, 2024 – Hovione Farmaciência, S.A. (“Hovione”) and Zerion Pharma A/S (“Zerion”) today announced that they have expanded their partnership to accelerate the development of the Dispersome® technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules. To this aim, the companies created a joint venture responsible for managing the Dispersome® intellectual property portfolio and allocated market rights to the two partners. Hovione and Zerion have been co-promoting the Dispersome® technology to clients since the beginning of 2022. Under the extended collaboration, Hovione is granted exclusive global rights to develop and offer the Dispersome® technology for drugs delivered via the respiratory route, a field where Hovione is active today with leading formulation and manufacturing capabilities. Further, Hovione is granted exclusive rights to develop and offer Dispersome® formulations for nutraceutical and medicinal foods products, an area with unmet needs in the area of bioavailability. Hovione is also granted a non-exclusive license to promote the Dispersome® technology for use in Pharmaceutical oral dosage forms for new chemical entities. In return for the grant of rights, Zerion will receive royalties from Hovione’s commercial activities in these fields. Within the framework of the joint venture, the parties will work closely together to bring the Dispersome® technology to customers as quickly as possible. Arla Foods Ingredients (Denmark) will deliver the pharmaceutical excipient (Lacprodan® BLG-100 Pharma Grade) for the Dispersome® technology, when BLG is accepted as a novel excipient. “Hovione is thrilled to reinforce its collaboration with Zerion to further accelerate the adoption of Dispersome® in the pharma and nutra markets,” said Jean-Luc Herbeaux, Hovione’s CEO. “The use of Zerion’s Dispersome® Technology has proven to deliver superior solubilization power for both pharma and nutraceutical active ingredients. This highly innovative platform is a valuable addition to Hovione’s leading offering in solubility and permeability enhancement for NCEs and nutraceuticals and affords formulators new options which address unmet needs of the industry.” Ole Wiborg, the CEO of Zerion, comments: “Hovione is the global leader in the field of producing amorphous solid dispersions by spray-drying and this extension of our partnership again confirms the huge potential of our Dispersome® technology. If one company in the pharma industry can truly judge its value, it is Hovione, and we have a strong belief in sharing our technology with Hovione, who will secure its use with more drugs and ingredients and in applications across several delivery routes. Thus, we expect substantial revenues from the collaboration in the years to come.” Through their partnership, Hovione and Zerion are offering pharma, biotech and nutra companies worldwide access to an innovative delivery platform combined with an unparalleled experience in formulation development, scale-up, and GMP manufacturing. The Dispersome® technology Zerion has pioneered the Dispersome® technology that addresses poor drug solubility, one of the most recognized drug development challenges. The Dispersome® technology increases solubility and bioavailability of poorly soluble compounds and can be applied at any stage of drug discovery or drug development, including in preclinical studies, first in human studies, and reformulation of existing drug products.   About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. About Zerion Pharma A/S Zerion develops its own proprietary drug formulations and offers its Dispersome® technology platform to established pharma companies as a means to solve their challenging drug solubility problems. Zerion was established in 2019 as a spinout of the University of Copenhagen.     Read the previous press releases on this story: Hovione and Zerion Pharma announce a strategic partnership to market the Dispersome® technology platform Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals  

Press Release
A partnership to accelerate the development of the Dispersome® technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules.

Hovione and Zerion Pharma create joint venture to further expand use of Dispersome® technology

Oct 03, 2024

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article
Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

Formulating Inhaled Medicines

Sep 24, 2024

From left to right: Jean-Luc Herbeaux, CEO of Hovione, Paula Alves, CEO of iBET, and João Almeida Lopes, President of iBET.   Lisbon, Portugal: Hovione, the specialist integrated CDMO and leader in spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnológica), a private not-for-profit research-intensive SME in the area of Biotechnology and Life Sciences, are proud to announce the official establishment of ViSync® Technologies as a jointly owned venture. The creation of this new company, headquartered in the Lisbon area of Portugal, illustrates the parent companies´ commitment to partnership and joint innovation. ViSync® will aim to develop innovative solutions to address the unmet technical needs of pharmaceutical companies in the cell and gene therapy space, leveraging Hovione's extensive expertise in pharmaceutical development, Particle Engineering and industrialization of pharmaceutical technologies and iBET's cutting-edge research in biotechnological sciences. One of the first focus areas of ViSync® will be to develop technologies that improve delivery and stabilization of new modality therapies. "We are delighted to join forces with iBET - a leading R&D organization in Biotechnology and Life Sciences – in the establishment of ViSync®.” says Jean-Luc Herbeaux, Hovione’s CEO. “By combining Hovione´s expertise in drug formulation, manufacturing process development and scale up with iBET´s broad understanding of new modalities, we aim to devise new solutions to help pharma companies launch innovative medicines and improve health outcomes for patients.”   “The creation of ViSync® marks a significant milestone for iBET.” says Paula Alves, CEO of iBET. “By combining our cutting-edge biotechnological research in the cell and gene therapy fields with Hovione’s extensive pharmaceutical development expertise, we are well-positioned to develop innovative approaches for targeted delivery and stabilization of new modality therapies. We are excited about the potential of ViSync® to drive substantial advancements and deliver significant benefits to patients worldwide.”    About Hovione  Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About iBET iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET’s core expertise lies on the development of bioprocesses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing.     iBET’s infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies.    iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders.    

Press Release
Commitment to partnership and joint innovation for cell and gene therapies

Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions

Sep 19, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
Hovione commitment to setting SBTs in line with the Paris Agreement

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of Hovione´s global expansion plans and marks a significant milestone in advancing Hovione's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote Hovione's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  “This strategic collaboration underscores Hovione's dedication to delivering innovative solutions and exceptional service to its customers,” said Yuken Kyoyama. “Our partnership with Higuchi will help to show customers in Japan how Hovione can meet their needs.”    Learn more about our business in Japan and visit our website hovione.co.jp    

News
Hovione proudly announces its collaborative venture with Higuchi.

Hovione forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Lisbon, Portugal: Hovione, the specialist integrated CDMO and leader in spray drying and particle engineering, is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.   The new line is the result of the partnership with GEA, a global leader in process technology for the pharmaceutical industry. Since announcing their partnership in 2022, Hovione and GEA have worked to advance continuous tableting technology. Their collaboration seeks to boost the adoption of continuous tableting by offering increased capacity, flexibility, standardized equipment, improved quality, and enhanced efficiency. Together, they have shown that continuous tableting can become a more accessible technology. This new R&D line is the only one of its kind in the world and perfectly replicates the most critical components of Hovione´s state-of-the-art commercial CT line in Loures, Portugal. It also offers a high degree of flexibility in throughput and can handle highly potent Active Pharmaceutical Ingredients (API). “With this new line, we will be able to optimize operating conditions with minimum amounts of API and provide a higher technical certainty when transferring from development to commercial scale”, said Jaime Del Campo, Head of R&D Services at Hovione. “The flexibility of the rig and the real-time process data monitoring capabilities contribute to a more agile design and upscaling experience.” The new CT line at Hovione's Lisbon R&D center is now fully operational and ready to support both existing and new projects. This investment reinforces Hovione's global reputation in pharmaceutical manufacturing and highlights the company's commitment to delivering innovative solutions that meet the evolving needs of the industry and support quicker and more efficient market launches.    About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.     Learn more about Continuous Tableting for Drug Product    

Press Release
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.

Hovione Unveils New Continuous Tableting Line at Lisbon R&D Centre

Jun 18, 2024

Following the creation of offices in Shanghai and Beijing, Hovione is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance Hovione´s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about Hovione´s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that Hovione is renowned for worldwide.   “The launch of the Hovione Chinese website underscores our commitment to customers in China,” said Ms. Jackie Liu, Country Head, China. “By delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients´ unique challenges with agility and precision.” Visit us at www.hovione.com.cn    

News
Hovione is closer to its customers with a new website in Mandarin

Hovione launches new website for the Chinese Market

Jun 14, 2024

Diane Villax, Co-Founder and Board Member of Hovione has been honored with a lifetime achievement award at Deloitte´s Investor Relations and Governance Awards (IRGAwards) 2024. It was especially fitting for her to receive this prestigious award, which recognizes individuals who have made valuable and exceptional contributions to their field, in the year that Hovione celebrates its 65th anniversary.   Learn more about IRGAwards  

News
36th edition of the Investor Relations & Governance Awards (IRGAwards) promoted by Deloitte

Diane Villax receives achievement award at Deloitte´s Investor Relations and Governance Awards (IRGAwards) 2024

May 23, 2024

Lisbon, May 21, 2024 – Hovione has placed fourth among the best companies to work in Portugal and was again the best in the Health Sector according to Randstad´s Employer Brand Research. The research, which was published yesterday, identified the 20 best employers in Portugal. This is the ninth annual edition of Ranstad´s study, which is based on a representative sample of the Portuguese workforce. The respondents evaluate companies according to a range of different criteria, including salary and benefits, job security, work atmosphere, and career progression opportunities. Employer branding can have a significant impact on an organization's ability to attract and retain top talent and so is becoming an increasingly important part of a company a strategy to address the talent shortage challenge.  Ilda Ventura, VP of Human Resources at Hovione explains that “Our global HR strategy is built on the need to attract, retain and empower our talented team members. Therefore, our Employer Branding needs to reflect the reality of who we are, so that we don’t just attract new talent but allow current team members to flourish. It also needs to capture the positive impact that Hovione has on the world, and how our innovative work relies on the knowledge and problem solving of our team members. We continue to work on refining and improving the work we do on our EB. This too is an important reflection of our values, and our belief in continuous improvement.” This is the third successive year that has been ranked as the most attractive company to work for in the Health Sector and placed in the top five overall  This recognition comes after Hovione was recognized as a Top Employer in all four of its global sites in January 2024, becoming the first company in Macau to do so.    About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.  

News
Hovione has placed fourth among the best companies to work in Portugal and was again the best in the Health Sector according to Randstad´s Employer Brand Research.

Hovione again ranks among best employers in Portugal

May 21, 2024

The new company, which will be located in Portugal, will focus on the development of drug delivery solutions for emerging drug modalities. Cell and gene therapies represent a paradigm shift in modern medicine, offering unprecedented opportunities to address previously untreatable diseases. ViSync solutions will help address some of the manufacturing challenges caused by the complex nature of new modalities, with special focus on stabilization, cell or tissue targeting and drug payload delivery.  Lisbon, 9th May 2024 – The specialist integrated CDMO and leader in pharmaceutical spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnológica), a private not-for-profit research intensive SME in the area of Biotechnology and Life Sciences, today announced the creation of ViSync Technologies, a new joint venture located in Oeiras, close to Lisbon. The newly formed company will focus on developing innovative technologies and scalable solutions to help pharmaceutical companies address formulation and manufacturing challenges in transformative cell and gene therapies. Hovione has a strong track record in industrializing new technologies and supporting Pharma Companies with their clinical and commercial volume manufacturing needs, while iBET has a strong biological background and a global reputation for its scientific knowledge of the new therapeutic modalities space, particularly cell and gene therapy.  New modalities, such as gene and cell therapies, RNA drugs and other complex biologics, are a rapidly growing segment of the pharmaceutical industry. They promise to bring breakthroughs to the treatment of a wide range of diseases and conditions, including cancer, genetic disorders, rare diseases and neurological conditions.  While this rapid growth has been driven by remarkable efficacy in addressing unmet clinical needs, the complex nature of the new modalities brings challenges, including limited drug administration options, immunogenic responses and off-target effects, issues with high dose delivery and high costs. The poor stability of these drugs is also an issue, resulting in the need for cold supply chains. ViSync will aim to develop novel technology platforms to address the unmet needs of pharmaceutical customers developing these transformative new products. “The creation of ViSync in collaboration with iBET marks an exciting new chapter in Hovione´s commitment to innovation”, said Dr Jean-Luc Herbeaux, Hovione´s CEO. “New therapeutic modalities have the potential to bring radical improvements to current standards of care and we are thrilled to partner with iBET, a world-renowned expert organization in this area, to develop technology platforms that help customers bring transformative therapies to patients worldwide. The first step will be to assemble a team who possesses the knowledge, expertise, and ingenuity needed to navigate the complexities ahead." “The establishment of ViSync in partnership with Hovione represents a pivotal moment in iBET’s dedication to pioneering research in advanced therapies,” stated Dr. Paula Alves, iBET’s CEO. “The immense promise of these new modalities is at our reach and we are delighted to join forces with Hovione, a globally recognized leader in technological industrialization and drug delivery. In this common endeavor, we will gather the scientific and technical competences and skills to support our clients and partners in delivering groundbreaking therapies to patients globally.” ViSync will develop its own lab facility in Lisbon and expects to be able to start its research and development work by the end of 2024.   About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About iBET iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET’s core expertise lies on the development of bioprocessses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing.  iBET’s infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies. iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders.  

News
News release, 09 May 2024

Hovione and iBET announce the creation of ViSync Technologies, an innovative new company that will develop solutions for unmet needs in cell and gene therapy

May 09, 2024

We are proud to have been nominated in three categories for HR Magazine’s annual awards, for Team Spirit and Engagement, Internal Mobility and Best HR Director. At Hovione, we talk about "Team Members” rather than “employees”, emphasizing the company's commitment to fostering a culture where teamwork is not just valued but integral to achieving collective success. We believe that individuals work best when they feel supported and are working towards a shared goal.  Hovione is a global company with a diverse range of roles across different disciplines. This means that we can offer team members the opportunity to explore new horizons and expand their skill sets within the company, enriching their career experiences and driving innovation across the organization. The awards are decided by a public vote which is open until the 17 May. Vote here!  

News
Place your vote.

Hovione nominated in HR Awards – voting is open globally

May 03, 2024

Contact Us

If you would like to learn more about Hovione, kindly fill in the form below and we will be revert to you soon.